retatrutide phase 2 trial obesity triple agonist Retatrutide: 3 Results (Up to 28.7% Weight Loss), Mechanism, Trials & 2026 Updates Lilly's triple agonist, retatrutide, delivered

Those treated with the vitamin C had chemosensitivity and reduced chemotherapy-associated toxicity

Unfortunately, this trial did not phenotype patients as T2 high or low, which might limit some of their conclusions for the future utility based on the correct patient population [96]

PMID: 37640530

Selenium at appropriate concentrations exhibits antioxidant and regulatory properties [5] and is considered to be a potential therapeutic agent [6]

Liu N, Cui X, Guo T et al (2024a) Baicalein ameliorates insulin resistance of HFD/STZ mice through activating PI3K/AKT signal pathway of liver and skeletal muscle in a GLP-1R-dependent manner